Answers are grounded in this paper and cite their sources.
Case series demonstrates clonal progression and SSTR2 expression in uterine neuroendocrine carcinoma, indicating potential for somatostatin-targeted therapies.
Background/Aim: mutation analysis, in order to contribute to the development of treatment strategies. Case Report: mutation analysis revealed a shared exon 4 point mutation in both components and an additional exon 7 point mutation only in the SCNEC component, suggesting clonal progression from ECAC to SCNEC. Conclusion: These cases suggest that uterine SCNEC may coexist with, and in some cases arise from, ECAC. SSTR2 expression in uterine SCNEC may have prognostic and therapeutic significance, supporting consideration of somatostatin analogues and future SSTR2-targeted strategies. Because coexisting histological subtypes such as ECAC may persist after treatment directed at SCNEC, therapeutic planning should include careful pathological assessment and consideration of multimodal treatment.
No takes yet. Share an insight, caveat, or question.
Bamba et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: